232 related articles for article (PubMed ID: 37047395)
1. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
[TBL] [Abstract][Full Text] [Related]
2. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
3. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
Yang F; Lin L; Li X; Wen R; Zhang X
Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
[TBL] [Abstract][Full Text] [Related]
4. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
5. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
[TBL] [Abstract][Full Text] [Related]
6. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
[TBL] [Abstract][Full Text] [Related]
11. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
[TBL] [Abstract][Full Text] [Related]
12. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936263
[TBL] [Abstract][Full Text] [Related]
15. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
17. Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
Yang ZY; Jiang CW; Zhang WL; Sun G
J Transl Med; 2022 Jun; 20(1):276. PubMed ID: 35717238
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
19. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
